Arcturus Therapeutics Inc. has obtained an award for up to US$63.2 million from the Biomedical Advanced Research and Development Authority (BARDA) to expand its current influenza vaccine program to include development of a pandemic influenza vaccine based on its proprietary self-amplifying mRNA platform.